Clinical trial
Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory…
NCT00258206 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00258206 |
|---|---|
| Title | Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma |
| Official title | Phase II Study of High Dose Cyclophosphamide and Rituximab in Multiple Myeloma |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological, Drug |
| Interventions | rituximab, cyclophosphamide |
| Enrollment | 21 |
| Start date | Dec 1, 2004 |
| Primary completion | Sep 7, 2007 |
| Completion | Sep 7, 2007 |
| First posted | Nov 24, 2005 |
| Last update posted | Dec 6, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: